About Noveome Biotherapeutics
Noveome Biotherapeutics is a private company based in Pittsburgh, Pennsylvania. It has reported $61,534,259 raised in six offerings on Form D since July 2012. Its chief executive is Patrick Welch.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 12, 2026 | Aug 27, 2026 | $6,750,503of $15.0M target | 6 | $1.1M | Debt, Convertible promissory notesRule 506(b) | Form D ↗ |
| Aug 2, 2023 | Aug 17, 2023amended Aug 8, 2024 | $36,184,531of $51.2M target | 66 | $548K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Sep 24, 2020 | Oct 2, 2020 | $870,000of $15.0M target | 7 | $124K | EquityRule 506(b) | Form D ↗ |
| Jan 12, 2018 | Jan 24, 2018amended Apr 22, 2019 | $15,000,000fully sold | 39 | $384K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Dec 31, 2015 | Jan 13, 2016amended Apr 14, 2016 | $2,158,479of $2.5M target | 39 | $55,346 | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Jun 30, 2012 | Jul 12, 2012 | $570,746fully sold | 15 | $38,050 | Equity06 | Form D ↗ |
| Total, six offerings | $61,534,259 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Noveome Biotherapeutics's Form D filed Aug 27, 2026.
Earlier filings also listed Gretchen Kraemer (executive officer, last listed Aug 2024), William Golden (chairman and chief executive officer, last listed Oct 2020), Terence Golden (director, last listed Oct 2020), Donald Wagner (director, last listed Oct 2020), John McArthur (director, last listed Apr 2019), A. Clarke Atwell (executive officer and director, last listed Apr 2016) and George Sing (executive officer and director, last listed Jul 2012).